|Home : About Us : Contact Us : Search : Site Map|
Other Names: Kaletra®, ABT-378/ritonavir, LPV/r
What is it?
Kaletra® belongs to a group of drugs known as protease inhibitors. It is used to treat HIV, a retrovirus. Retroviruses use the genetic material in the body’s cells to produce more virus which can infect other cells.
How does it work?
Kaletra® interferes with the life cycle of HIV to stop it from producing more virus. Specifically, Kaletra® ties up the protease enzyme, which slows the production of new virus to prevent other cells from becoming infected. This medication is used in combination with other antiretroviral drugs to inhibit HIV reproduction.
How do I take it?
It is extremely important that you take lopinavir/ritonavir and your other antiretroviral medications exactly as directed. You should set up a system that will help you remember to take your medicines so that you do not miss any doses. If you miss a dose, take it as soon as possible; however, if you skip a dose, do not take two doses at once. Do not stop taking the medication for any reason at any time unless you are directed to do so by your study clinician. If you are unable to continue taking your medication due to side effects, you should contact your study clinician immediately.
Some drugs taken together may have interactions that cause illness or impair the effectiveness of the drugs. Lopinavir/ritonavir has a number of serious drug interactions. You need to be familiar with the names of medications that you are taking and compare them to the medications listed below. Make sure that everyone who is prescribing or dispensing medications to you knows that you are taking lopinavir/ritonavir.
Lopinavir/ritonavir should not be taken with any of the following medicaitons:
Many other drugs may interact with lopinavir/ritonavir so you must tell your study clinician about all medications you are currently taking. This includes any medications that you may take on an ‘as needed’ basis, such as sleeping pills or pain medications and herbal or natural medicines. Also, you need to always check with your study clinician before starting any new medications.
Not everyone experiences side effects. When they do occur, they may be mild, moderate or severe. Some side effects cannot be felt by the patient but can be found through laboratory tests, so it is important to see your study clinician regularly for checkups so that side effects can be detected early and treated.
The most common side effects of lopinavir/ritonavir are: diarrhea, headache, nausea, dry mouth, abdominal pain, dyspepsia (heartburn), vomiting, rash, and asthenia (weakness or lack of energy). Other reported side effects include increases in liver enzymes (a measure of how your liver is functioning), and increased amylase (an increase may indicate a problem with your pancreas).
Increases in blood sugar or the development of diabetes has been reported in a small number of patients taking protease inhibitors. Symptoms include increased thirst or hunger, weight loss, increased need to urinate, fatigue, or dry, itchy skin. Please contact your study clinician if any of these side effects occur.
Also, a condition called lipodystrophy (abnormal use of fats in the body) has been reported in patients taking protease inhibitors. Symptoms vary among individuals, but they may include accumulation of fat tissue in the stomach area or the upper back, and a loss of mass in other areas of the body. Some people have experienced increases in cholesterol and triglycerides that have required the use of lipid lowering medications.
The benefits of taking protease inhibitors far outweigh the risk of developing lipodystrophy or diabetes. Therefore, at this time, we strongly encourage you to take your medications exactly as prescribed. Notify your study clinician if any of these side effects are bothersome and may prevent you from taking your medication.
|FOR PATIENTS : FOR PROVIDERS : PHARMACY : CALENDAR : RESOURCES
About Us : Contact Us : Search : Site Map : Harborview Medical Center : UW Medical Center
| Copyright © 2005 University of Washington. All rights reserved.
Notice of Privacy Practices : Copyright and Disclaimer : Credits and Acknowledgements